134 related articles for article (PubMed ID: 1551909)
1. Characterization of recombinant C1 inhibitor P1 variants.
Eldering E; Huijbregts CC; Lubbers YT; Longstaff C; Hack CE
J Biol Chem; 1992 Apr; 267(10):7013-20. PubMed ID: 1551909
[TBL] [Abstract][Full Text] [Related]
2. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
[TBL] [Abstract][Full Text] [Related]
3. Expression of functional human C1 inhibitor in COS cells.
Eldering E; Nuijens JH; Hack CE
J Biol Chem; 1988 Aug; 263(24):11776-9. PubMed ID: 2841334
[TBL] [Abstract][Full Text] [Related]
4. Chymotrypsin inhibitory activity of normal C1-inhibitor and a P1 Arg to His mutant: evidence for the presence of overlapping reactive centers.
Aulak KS; Davis AE; Donaldson VH; Harrison RA
Protein Sci; 1993 May; 2(5):727-32. PubMed ID: 8495195
[TBL] [Abstract][Full Text] [Related]
5. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein.
Zahedi R; Bissler JJ; Davis AE; Andreadis C; Wisnieski JJ
J Clin Invest; 1995 Mar; 95(3):1299-305. PubMed ID: 7883978
[TBL] [Abstract][Full Text] [Related]
6. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition.
Zahedi R; MacFarlane RC; Wisnieski JJ; Davis AE
J Immunol; 2001 Aug; 167(3):1500-6. PubMed ID: 11466370
[TBL] [Abstract][Full Text] [Related]
7. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
Sulikowski T; Bauer BA; Patston PA
Protein Sci; 2002 Sep; 11(9):2230-6. PubMed ID: 12192078
[TBL] [Abstract][Full Text] [Related]
8. The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants.
Eldering E; Huijbregts CC; Nuijens JH; Hack CE
Behring Inst Mitt; 1993 Dec; (93):125-30. PubMed ID: 8172559
[No Abstract] [Full Text] [Related]
9. Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding.
Rossi V; Bally I; Ancelet S; Xu Y; Frémeaux-Bacchi V; Vivès RR; Sadir R; Thielens N; Arlaud GJ
J Immunol; 2010 May; 184(9):4982-9. PubMed ID: 20351192
[TBL] [Abstract][Full Text] [Related]
10. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
Zahedi R; Wisnieski J; Davis AE
J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
[TBL] [Abstract][Full Text] [Related]
11. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms.
Davis AE; Aulak K; Parad RB; Stecklein HP; Eldering E; Hack CE; Kramer J; Strunk RC; Bissler J; Rosen FS
Nat Genet; 1992 Aug; 1(5):354-8. PubMed ID: 1363816
[TBL] [Abstract][Full Text] [Related]
12. Characterization of C1 inhibitor-Ta. A dysfunctional C1INH with deletion of lysine 251.
Zahedi R; Aulak KS; Eldering E; Davis AE
J Biol Chem; 1996 Sep; 271(39):24307-12. PubMed ID: 8798678
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human complement subcomponent C1s lacking beta-hydroxyasparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex.
Luo C; Thielens NM; Gagnon J; Gal P; Sarvari M; Tseng Y; Tosi M; Zavodszky P; Arlaud GJ; Schumaker VN
Biochemistry; 1992 May; 31(17):4254-62. PubMed ID: 1533159
[TBL] [Abstract][Full Text] [Related]
14. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS
Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
[TBL] [Abstract][Full Text] [Related]
15. Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.
Donaldson VH; Harrison RA; Rosen FS; Bing DH; Kindness G; Canar J; Wagner CJ; Awad S
J Clin Invest; 1985 Jan; 75(1):124-32. PubMed ID: 3965500
[TBL] [Abstract][Full Text] [Related]
16. Functional and structural similarities between protease nexin I and C1 inhibitor.
Van Nostrand WE; McKay LD; Baker JB; Cunningham DD
J Biol Chem; 1988 Mar; 263(8):3979-83. PubMed ID: 3279027
[TBL] [Abstract][Full Text] [Related]
17. Structure and function of C1 inhibitor.
Davis AE
Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
[TBL] [Abstract][Full Text] [Related]
18. C1 dissociation. Spontaneous generation in human serum of a trimer complex containing C1 inactivator, activated C1r, and zymogen C1s.
Laurell AB; Mårtensson U; Sjöholm AG
J Immunol; 1987 Dec; 139(12):4145-51. PubMed ID: 2826582
[TBL] [Abstract][Full Text] [Related]
19. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
Harpel PC; Cooper NR
J Clin Invest; 1975 Mar; 55(3):593-604. PubMed ID: 123251
[TBL] [Abstract][Full Text] [Related]
20. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.
Skriver K; Wikoff WR; Patston PA; Tausk F; Schapira M; Kaplan AP; Bock SC
J Biol Chem; 1991 May; 266(14):9216-21. PubMed ID: 2026621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
